Selenium (Se) is a part of the enzyme glutathione peroxidase, which metabolizes hydroperoxides formed from polyunsaturated fatty acids. Selenium is also a part of the enzymes that deiodinate thyroid hormones. Generally, selenium acts as an antioxidant that works with vitamin E.
(See also Overview of Mineral Deficiency and Toxicity.)
Some epidemiologic studies associate low selenium levels with cancer. However, a study showed that selenium supplements did not prevent future colorectal adenomas in patients who had colorectal adenomas removed (1), and overall, no evidence suggests that selenium supplements prevent cancer (2).
Plasma levels of selenium vary from 8 to 25 mcg/dL (0.1 to 0.3 micromoles/L), depending on selenium intake.
Selenium deficiency is rare, even in New Zealand and Finland, where selenium intake is 30 to 50 mcg/day, compared with 100 to 250 mcg/day in the US and Canada.
In certain areas of China, where intake averages 10 to 15 mcg/day, selenium deficiency predisposes patients to Keshan disease, an endemic viral cardiomyopathy affecting primarily children and young women. This cardiomyopathy can be prevented but not cured by sodium selenite supplements of 50 mcg/day orally.
Patients receiving long-term total parenteral nutrition have developed selenium deficiency with muscle pain and tenderness that responded to a selenomethionine supplement.
In Siberian Russia and China, growing children with selenium deficiency may develop chronic osteoarthropathy (Kashin-Beck disease).
Selenium deficiency may contribute synergistically with iodine deficiency to the development of goiter and hypothyroidism (3).
Diagnosis of selenium deficiency is made clinically or sometimes by measuring glutathione peroxidase activity or plasma selenium, but neither of these tests is readily available.
Treatment of selenium deficiency consists of sodium selenite 100 mcg/day orally.
Довідкові матеріали загального характеру
1. Thompson PA, Ashbeck EL, Roe DJ, et al: Selenium supplementation for prevention of colorectal adenomas and risk of associated type 2 diabetes. J Natl Cancer Inst 108 (12), 2016. doi: 10.1093/jnci/djw152
2. Vinceti M, Filippini T, Del Giovane C, et al: Selenium for preventing cancer. Cochrane Database Syst Rev 1 (1):CD005195, 2018. doi:10.1002/14651858.CD005195.pub4
3. Winther KH, Rayman MP, Bonnema SJ, Hegedus L: Selenium in thyroid disorders—essential knowledge for clinicians. Nat Rev Endocrinol 16:165–176, 2020. doi: 10.1038/s41574-019-0311-6